Response to: Randomized, assessor-blinded trial comparing highly purified human menotropin and recombinant follicle-stimulating hormone in high responders undergoing intracytoplasmic sperm injection

Affiliations

¹ Global Medical Affairs Fertility, R&D Biopharma, Merck KGaA, Darmstadt, Germany.
² Global Medical Affairs Fertility, R&D Biopharma, Merck KGaA, Darmstadt, Germany; International PhD School in Clinical and Experimental Medicine (CEM), University of Modena and Reggio Emilia, Modena, Italy.

Comment

Ana Rita Batista et al. Fertil Steril. 2024 Feb.

. 2024 Feb;121(2):358.

doi: 10.1016/j.fertnstert.2023.09.008. Epub 2023 Sep 19.

¹ Global Medical Affairs Fertility, R&D Biopharma, Merck KGaA, Darmstadt, Germany.
² Global Medical Affairs Fertility, R&D Biopharma, Merck KGaA, Darmstadt, Germany; International PhD School in Clinical and Experimental Medicine (CEM), University of Modena and Reggio Emilia, Modena, Italy.

No abstract available

Conflict of interest statement

Declaration of interests AR.B., J.E.S. and M.L. are employees of Merck Healthcare, Darmstadt, Germany.

Randomized, assessor-blinded trial comparing highly purified human menotropin and recombinant follicle-stimulating hormone in high responders undergoing intracytoplasmic sperm injection.
Witz CA, Daftary GS, Doody KJ, Park JK, Seifu Y, Yankov VI, Heiser PW; Menopur in GnRH Antagonist Cycles with Single Embryo Transfer – High Responder (MEGASET-HR) Trial Group. Witz CA, et al. Fertil Steril. 2020 Aug;114(2):321-330. doi: 10.1016/j.fertnstert.2020.03.029. Epub 2020 May 13. Fertil Steril. 2020. PMID: 32416978 Clinical Trial.